AvKARE Recalls Celecoxib Capsules Over Tadalafil Cross-Contamination, Highlighting Persistent QC Issues
AvKARE has initiated a Class II recall of Celecoxib Capsules due to Tadalafil cross-contamination, affecting 3,817 cartons nationwide. This incident underscores AvKARE's recurring quality control challenges, including previous mix-ups and impurities. Procurement and regulatory teams must assess supply chain risks and consider alternative suppliers to mitigate potential disruptions and ensure patient safety.
What the FDA Found: AvKARE's Celecoxib Contamination Incident
AvKARE, a U.S.-based manufacturer, has initiated a voluntary Class II recall, identified as D-0460-2025, for its Celecoxib Capsules, 200 mg. This critical action, reported to the FDA on June 18, 2025, stems from a significant quality control failure: the discovery of a 5mg tadalafil tablet within a 500-count bottle of Celecoxib 200 mg capsules. The affected product, specifically Lot #47881 with an expiration date of May 31, 2026, was distributed nationwide across the USA. A total of 3,817 50-count cartons (NDC 50268-169-15) are subject to this ongoing recall. For procurement directors, this incident necessitates an immediate review of inventory sourced from AvKARE, particularly for Celecoxib (a Nonsteroidal Anti-inflammatory Drug, HSN 29339900). The presence of tadalafil, a Phosphodiesterase 5 Inhibitor used for erectile dysfunction, in a pain medication poses a serious patient safety risk due to potential drug interactions and adverse effects, especially for individuals unaware they are consuming an unprescribed active pharmaceutical ingredient. Regulatory affairs heads must assess the implications for product integrity and compliance, initiating investigations into their own supply chains to identify and quarantine affected stock. Supply chain VPs should quantify the potential for supply disruption for this specific Celecoxib dosage and begin contingency planning.
AvKARE's Operational Footprint and Product Portfolio
AvKARE operates its formulation facility in Pulaski, Tennessee, United States, serving as a key manufacturer in the U.S. generic pharmaceutical market. While the specific manufacturing details for Celecoxib Capsules are tied to this location, the company's broader product portfolio, as evidenced by past regulatory actions, spans a diverse range of therapeutic areas. This includes products such as Pregabalin (CNS), Chloroquine Phosphate (Antiparasitics), Mirtazapine (Central Nervous System), Diclofenac (Dermatology), and many others, all primarily falling under HSN code 29339900. For business development executives, this broad portfolio indicates AvKARE's significant market presence in generic pharmaceuticals. However, the recurring nature of quality control issues, including foreign substance contamination and mix-ups, introduces considerable risk when evaluating AvKARE as a potential partner or competitor. Procurement directors relying on AvKARE for a wide array of generic medications must recognize that quality control lapses in one product line can signal systemic vulnerabilities affecting their entire supply. This event highlights the necessity of robust supplier qualification processes that extend beyond initial audits to continuous performance monitoring across all sourced products.
Supply Chain Exposure: Implications for Celecoxib Procurement
The recall of AvKARE's Celecoxib Capsules, 200 mg, directly impacts procurement strategies for this widely used Nonsteroidal Anti-inflammatory Drug (NSAID). With 3,817 50-count cartons distributed nationwide in the USA, companies sourcing this specific product (NDC 50268-169-15) face immediate supply chain disruption. The core issue—cross-contamination with tadalafil 5mg—is particularly concerning. Tadalafil, a Phosphodiesterase 5 Inhibitor, is a potent drug with different indications and potential side effects compared to Celecoxib, creating significant patient safety risks. For supply chain VPs, this means an urgent need to identify all affected inventory, initiate quarantine procedures, and manage returns. The recall’s Class II classification, while not the highest severity, still indicates that the use of the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. Regulatory affairs heads must ensure all downstream partners are notified and compliant with recall instructions. Furthermore, the incident necessitates a re-evaluation of quality agreements with AvKARE, focusing on enhanced inspection protocols and tighter controls to prevent future cross-contamination events, especially given the company's history of similar issues.
Strategic Alternatives for Celecoxib Supply
While the knowledge graph does not specify alternative suppliers for Celecoxib (HSN 29339900) directly, procurement directors must proactively identify and qualify alternative sources to mitigate reliance on AvKARE, particularly given their recurring compliance challenges. General alternative suppliers for AvKARE's broader product portfolio include Aurohealth, Granules India, NorthStar Rx, NURAY CHEMICALS, Indoco Remedies, Armas Pharmaceuticals, Societal CDMO Gainesville, and Apotex. These companies represent potential diversification options across various geographies, including India and Canada, which can enhance supply chain resilience. For procurement teams, the immediate action involves initiating due diligence on these or other potential suppliers to assess their manufacturing capabilities, quality systems, and regulatory compliance records. Qualification timelines for new suppliers can range from 6 to 18 months, depending on the complexity of the molecule and regulatory requirements, emphasizing the need for prompt action. Business development executives may also identify opportunities to partner with more reliable manufacturers to fill potential market gaps created by AvKARE's ongoing issues. Diversifying the supplier base geographically reduces single-point-of-failure risks and strengthens overall supply chain stability for critical generic medications.
AvKARE's Recurring Compliance Challenges
This Celecoxib recall is not an isolated event for AvKARE but rather a continuation of a concerning pattern of quality control and compliance issues. The company has faced multiple recalls in recent years, highlighting systemic vulnerabilities in its manufacturing and packaging processes. In 2020, AvKARE initiated a recall for Dutasteride due to impurity failures and another for Lamotrigine due to foreign substance contamination. Most notably, in December 2020, the company faced a high-severity Class I recall for a Trazodone-Sildenafil mix-up at a third-party facility, an incident strikingly similar in nature to the current Celecoxib-Tadalafil contamination. More recently, AvKARE initiated a high-severity recall for Cinacalcet tablets in December 2024 over nitrosamine impurity concerns and a low-severity recall for Carboxymethylcellulose Sodium Ophthalmic Solution in January 2025 due to a label mix-up. For regulatory affairs heads, this history indicates a persistent inability to maintain consistent Good Manufacturing Practices (GMP). This pattern increases the risk of further FDA enforcement actions, including potential Warning Letters or even Import Alerts, which could severely impact AvKARE's ability to supply the U.S. market. Supply chain VPs should factor this elevated risk profile into their long-term sourcing strategies, as continued reliance on AvKARE may expose their organizations to unacceptable levels of supply and regulatory risk.
Outlook: Remediation and Future Regulatory Scrutiny
The ongoing Class II recall of AvKARE's Celecoxib Capsules necessitates a comprehensive remediation effort from the company, which will be under intense FDA scrutiny. AvKARE is expected to conduct a thorough root cause analysis to determine how a tadalafil 5mg tablet ended up in Celecoxib bottles and implement robust corrective and preventive actions (CAPAs). Given the company's history of similar mix-ups and foreign substance contaminations, the FDA is likely to demand significant improvements to quality management systems, including enhanced segregation protocols, automated inspection technologies, and more rigorous personnel training. For regulatory affairs heads, this means closely monitoring AvKARE's response and the FDA's subsequent evaluations. Failure to adequately address these issues could escalate to more severe enforcement actions, such as an FDA Warning Letter or even placement on an Import Alert, which would effectively halt shipments of affected products into the U.S. For procurement directors, this ongoing uncertainty underscores the urgency of diversifying their supplier base for Celecoxib and other generics currently sourced from AvKARE. Business development executives should anticipate market shifts as customers seek more reliable suppliers, potentially creating opportunities for competitors with strong compliance records.